Beta Bionics, Inc.
BBNX
NASDAQ·Healthcare·Medical - Devices·Mkt cap $873.7M
$19.42
▼ -2.51%
P/E
-11.77
Mkt Cap
$873.7M
52-Wk Range
$8.80–$32.71
52-Week Range
$8.80 - $32.71
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 16.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary bionic pancreas technology with proven clinical efficacy and FDA approval
- Strategic partnerships with Xeris Pharmaceuticals and Abbott Diabetes Care enhancing product development and commercialization
- Innovative tubeless Patch Pump design addressing patient comfort and adherence challenges
- Expansion into type 2 diabetes market, capturing underserved patient population
Bear Case
1 risk
- Very high volatility (beta 3.4). Expect 3x market swings. Position size accordingly.
Growth
Moderate growth ahead
Increasing global prevalence of type 1 and type 2 diabetes requiring insulin therapy
Value
Trading at 0.0x sector peers — a discount despite the growth profile.
Momentum
Hot
+40.0% over 3m
Quality
Strong
High-growth business (53% revenue growth, 58% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying BBNX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 29, 2026
Reported EPS of -$0.53 vs -$0.58 consensus (+8.8% surprise). Revenue of $32.0M vs $31.5M expected (+1.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+8.8%
Revenue trend · last 8Q
—
+145%
+36%
+54%
+63%
+57%
+57%
+38%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$16.7M
$20.4M
$17.6M
$23.2M
$27.3M
$32.1M
$27.6M
$32.0M
Margins · last 8Q
Gross
59.0%
Operating
-79.9%
Profit
-73.1%
Wall Street consensus
6 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: William Blair · Aug 21, 2026
vs Industry
How BBNX stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related